Azeliragon

603148-36-3

532.12

H2O : < 0.1 mg/mL (insoluble); DMSO : 50 mg/mL (93.96 mM; Need ultrasonic)

Neuronal Signaling

Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer's disease (AD)^[1]. Azeliragon also can cross the blood-brain barrier (BBB)^[2]. In Vitro: Azeliragon (4 nM; 16 hours; T cells) treatment inhibits of wild type mice (WT) but not the deletion of the receptor (RAGE-/- mice) T cells and significant reduction in the production of IFN-gamma^[3]. In Vivo: Azeliragon (100 mcg/d; intraperitoneal injection; every day) treatment reduces syngeneic islet graft and islet allograft in NOD and B6 mice (Islets were isolated from young prediabetic NOD/LtJ mice and transplanted into NOD mice with spontaneous diabetes; islets were isolated from WT BALB/c mice and transplanted into B6 mice with diabetes)^[3].